PALO ALTO, Calif.--(BUSINESS WIRE)--April 3, 2006--Connetics Corporation (NASDAQ:CNCT - News), a specialty pharmaceutical company that develops and commercializes dermatology products, today announced the filing of a Citizen Petition with the U.S. Food and Drug Administration (FDA) to request that any generic products that reference Soriatane® (acitretin) meet several criteria in addition to rigorous bioequivalency testing prior to approval. The criteria outlined in the Citizen Petition will ensure that patients are adequately protected from generic versions of acitretin that might not be comparable in safety and efficacy to the branded product.
